New Blood Filter Shows Promise Against Deadly Sepsis

A new medical device that filters blood to remove a dangerous protein could transform treatment for sepsis, a condition that kills nearly 40 percent of patients even with current therapies.

The experimental treatment removes galectin-3, a protein that appears to drive the deadly immune overreaction in sepsis. By extracting blood plasma, filtering out this protein, and returning the cleaned blood to patients, researchers have achieved remarkable results in early testing.

Sepsis occurs when the body's immune system attacks its own tissues while fighting infection. In 2017 alone, 49 million people worldwide developed the condition. Despite available treatments for the underlying infections, roughly one in three sepsis patients dies within 90 days.

Dr. Isaac Eliaz spent decades studying galectin-3 before realizing it might be a key player in sepsis. Research showed that patients with higher levels of this protein faced greater risk of death. That discovery led his team to create a specialized filtering device.

The device works through a process called apheresis. Blood is drawn from the patient and spun in a centrifuge to separate cells from plasma. The plasma then passes through antibody-coated filters that capture galectin-3 before the cleaned blood returns to the body.

Researchers at Zhongnan Hospital of Wuhan University put the device through rigorous testing. They confirmed that sepsis patients had elevated galectin-3 levels and that survivors saw those levels drop naturally over time.

Then came the breakthrough animal trials. In rats with sepsis, 57 percent of those receiving the blood filtration survived compared to just 25 percent in the control group. Similar tests in miniature pigs showed survival jump from 27 percent to 69 percent.

The Bright Side

The treatment addresses a critical gap in sepsis care. While doctors can treat underlying infections and support failing organs, they've had no way to stop the immune system's destructive cascade. This device targets that missing piece directly.

Dr. Djillali Annane, a sepsis expert in France, calls the approach innovative and notes the consistent results across different animal models. He emphasizes the need for additional testing and deeper understanding of how galectin-3 drives sepsis at the molecular level.

Independent researchers will need to replicate these findings, and primate studies remain necessary before human trials begin. Still, the company behind the device aims to launch randomized clinical trials in people by 2027.

For the millions affected by sepsis each year, this blood filtration approach offers something families have desperately needed: genuine hope that more patients could survive this devastating condition.